Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SBFM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSunshine Biopharma raises $6M in dilutive public offering with 24M warrants issued
Filed May 19, 2026 · Period ending May 18, 2026 · ~1 min read
Key Changes
-
high
Company sold 12M units at $0.50 each, raising ~$6M gross. Each unit includes one share plus two warrants exercisable at $0.50, creating 24M warrants that could raise another $12M but would significantly dilute shareholders.
Item 1.01 verify on EDGAR → -
high
Series C Warrants are immediately exercisable at $0.50 per share and expire in five years. Full exercise of all 24M warrants would double the current share count from this offering alone.
Item 1.01 verify on EDGAR → -
medium
Warrants contain downward anti-dilution protection: if stock price falls below $0.50 after certain corporate actions, exercise price can drop to $0.25 with proportional increase in shares issuable, amplifying dilution risk.
Item 1.01 verify on EDGAR → -
medium
Placement agent Aegis Capital received 9% of gross proceeds ($540K) plus reimbursable expenses, reducing net capital available for operations.
Item 1.01 verify on EDGAR → -
low
840K pre-funded warrants with $0.00001 exercise price are economically equivalent to common shares and likely to be exercised immediately, representing immediate dilution.
Item 1.01 verify on EDGAR →
Summary
Sunshine Biopharma completed a $6 million public offering on May 19, 2026, selling units consisting of common stock and warrants at $0.50 per unit. The offering created immediate dilution of approximately 12 million shares, but the bigger concern is the 24 million warrants issued—two per unit—that are immediately exercisable at $0.50 and don't expire for five years.
If fully exercised, these warrants would raise an additional $12 million but would more than double the dilution from this transaction. Retail investors should understand that this is a highly dilutive financing structure typical of small biopharma companies that need capital but have limited access to traditional financing.
The warrants include downward anti-dilution provisions that could reduce the exercise price to as low as $0.25 if certain corporate actions trigger price declines, potentially amplifying dilution further. After deducting the 9% placement agent fees, the company netted approximately. Watch for warrant exercise activity over the coming months and quarters, particularly if the stock trades above $0.50. Any significant warrant exercises will appear in subsequent quarterly filings and will directly increase the share count, diluting existing holders. Also monitor how quickly the company depletes this capital, as another financing round within 12-18 months could signal ongoing cash burn concerns.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Sunshine Biopharma raised ~$6M via public offering of 11.16M common units and 840K pre-funded units at $0.50/unit, closing May 19, 2026.
Added in current filing · verify on EDGAR →
On May 18, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering (the “Offering”) of (A) 11,160,000 Common Units, with each Common Unit consisting of (i) one share (the “Shares”) of the Company’s common stock (“Common Stock”), and (ii) two Series C warrants (the “Series C Warrants”), each Series C Warrant exercisable for one share of Common Stock; and (B) 840,000 Pre-Funded Units, each Pre-Funded Unit consisting of (i) one pre-funded warrant (the “Pre-Funded Warrants”) to purchase one share of Common Stock, and (ii) two Series C Warrants. The purchase price of each Common Unit was $0.50, and the purchase price of each Pre-Funded Unit was $0.49999.
The company completed a public offering selling 11,160,000 common units at $0.50 each and 840,000 pre-funded units at $0.49999 each. Each unit includes one share (or pre-funded warrant) plus two Series C warrants. The offering closed May 19, 2026 and raised approximately $6 million in gross proceeds before fees.
Added in current filing · verify on EDGAR →
If the Company effects any share split, share dividend, share combination, recapitalization or other similar transaction involving the Company’s common stock (a “Share Combination Event”), and the lowest volume weighted average price of the common stock during the period commencing five consecutive trading days immediately preceding and ending five consecutive trading days immediately following the Share Combination Event is less than the then-effective exercise price of the Series C Warrants, then the exercise price will be reduced (but not increased) to such lowest volume weighted average price, subject to a minimum exercise price of $0.25 (50% of the initial exercise price), and the number of shares issuable upon exercise will increase so that the aggregate exercise price payable upon full exercise of the Series C Warrants after such adjustment equals the aggregate exercise price payable upon full exercise immediately prior to such adjustment.
The Series C Warrants contain a downward-only anti-dilution adjustment triggered by share splits or similar events if the stock price falls below the warrant exercise price. The exercise price can be reduced to as low as $0.25, with the number of shares issuable increasing proportionally to maintain the same aggregate exercise value. This provision requires stockholder approval per Nasdaq rules.
Added in current filing · verify on EDGAR →
Under the terms of the Placement Agent Agreement, the Placement Agent received a fee of 7% of the public offering price for the Offering and a non-accountable expense allowance of 2% of the public offering price. In addition, the Company reimbursed certain accountable expenses of the Placement Agent.
Aegis Capital Corp. received 7% of gross proceeds as placement agent fees plus a 2% non-accountable expense allowance, totaling approximately $540,000 on the $6 million raise, plus additional reimbursable expenses. These fees reduce the net proceeds available to the company.
Event · Item 8.01 — Other Events
Company announced pricing and closing of an offering on May 18-19, 2026.
Added in current filing · verify on EDGAR →
On May 18, 2026, the Company issued a press release announcing the pricing of the Offering.
The company disclosed that it priced an offering on May 18, 2026. The 8-K does not provide details on the offering size, price, or terms, referring only to attached press releases for specifics.
Added in current filing · verify on EDGAR →
On May 19, 2026, the Company issued a press release announcing the closing of the Offering.
The company disclosed that the offering closed on May 19, 2026, one day after pricing. This indicates the transaction completed successfully, though specific financial terms are not provided in the 8-K body itself.
Event · Item 9.01 — Financial Statements and Exhibits
Sunshine Biopharma disclosed a financing transaction involving a placement agent, pre-funded warrants, and Series C warrants.
Added in current filing · verify on EDGAR →
Placement Agent Agreement
The company entered into a Placement Agent Agreement, indicating a capital raising transaction facilitated by a third-party placement agent. This typically involves the issuance of securities to investors, though specific terms are not disclosed in the 8-K body itself.
Added in current filing · verify on EDGAR →
Form of Pre-Funded Warrant
The company issued pre-funded warrants, which are securities that allow holders to purchase shares at a nominal exercise price. This is a common structure in registered direct offerings or private placements, potentially resulting in dilution to existing shareholders.
Added in current filing · verify on EDGAR →
Form of Series C Warrant
The company issued Series C Warrants, which grant holders the right to purchase shares at a specified price within a certain timeframe. The issuance of warrants can lead to future dilution if exercised.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify